- Global Pharma News & Resources

Market Opportunities to 2023: Molecular Diagnostics for Infectious Diseases - Startup Prominex Raises $4M in Series A1

Market Opportunities to 2023: Molecular Diagnostics for Infectious Diseases - Startup Prominex Raises $4M in Series A1

PR Newswire

DUBLIN, Nov. 8, 2018

DUBLIN, Nov. 8, 2018 /PRNewswire/ --

The "Molecular Diagnostics for Infectious Disease. Markets, Strategies and Trends. Volume & Price Forecasts by Pathogen and by Country. With Multiplex and Point of Care Market Analysis, Executive Guides and Customization. 2019 to 2023 - Global Version" report has been added to's offering.

Multiplex testing threatens existing infectious disease practice. The microbiology lab may disappear.

The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for record growth.

A market that just keeps on growing. In spite of the steady decline of disease prevalence, the diagnostic sector keeps growing. Find out about the exciting developments in multiplex assays which threaten to change diagnosis and treatment while limiting the threat of anti microbial drug resistance.

Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics.

A range of dynamic trends are pushing market growth and company valuations. Trends like:

  • multiplex testing
  • emerging economies and global prosperity
  • biotechnology advances in genetics
  • pathogen evolution
  • climate change
  • globalization
  • the rise of rapid testing

Exciting technical developments especially in the seesaw between sequencing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.

The report has hundreds of pages of information including a complete list of Current 2016 United States Medicare Fee Payment Schedules to help sharpen your pricing.

Key Topics Covered

1. Introduction and Market Definition
1.1 What is Molecular Diagnostics
1.2 The Diagnostics Revolution
1.3 Market Definition
1.3.1 Volumes
1.3.2 Prices
1.3.3 Revenue Market Size
1.4 Methodology
1.4.1 Authors
1.4.2 Sources
1.5 U.S. Medical Market and Clinical Laboratory Testing - Perspective
1.5.1 U.S. Medicare Expenditures for Clinical Testing

2. The Infectious Diseases - Market Analysis by Disease
2.1 HIV - Human Immunodeficiency Virus (AIDS)
2.1.1 Virology Classification Structure and genome Tropism Replication cycle Genetic variability
2.1.2 Diagnosis
2.1.3 Testing Antibody tests Point of Care Tests (POCT) Antigen Tests Nucleic acid-based tests (NAT) Other tests used in HIV treatment
2.1.4 Market Opportunity Analysis
2.2 HBV - Hepatitis B
2.2.1 Virology Genome Pathogenesis Hepatitis B virus replication Serotypes and genotypes
2.2.2 Mechanisms
2.2.3 Diagnosis
2.2.4 Market Opportunity Analysis
2.3 HCV - Hepatitis C
2.3.1 Taxonomy
2.3.2 Structure Genome
2.3.3 Molecular biology
2.3.4 Replication
2.3.5 Genotypes Clinical importance
2.3.6 Market Opportunity Analysis
2.4 HPV - Human papillomavirus
2.4.1 Virology E6/E7 proteins Role in cancer E2 research Latency period Clearance
2.4.2 Diagnosis Cervical testing Oral testing Testing men Other testing
2.4.3 Market Opportunity Analysis
2.5 Influenza
2.5.1 Virology Types of virus Influenzavirus A Influenzavirus B Influenzavirus C Structure, properties, and subtype no Replication
2.5.2 Testing Advantages/Disadvantages of Molecular Assays
2.5.3 Market Opportunity Analysis
2.6 CTGC - Chlamydia/Gonorhea
2.6.1 Gonorrhea Diagnosis Screening
2.6.2 Chlamydia Diagnosis Screening
2.6.3 Testing Nucleic acid amplification tests (NAATs) Performance of NAAT Tests
2.6.4 Market Opportunity Analysis
2.7 Tuberculosis
2.7.1 Mycobacteria
2.7.2 Diagnosis Active tuberculosis Latent tuberculosis
2.7.3 Epidemiology
2.7.4 Molecular Diagnostic Tests
2.7.5 Market Opportunity Analysis
2.8 MRSA - Methicillin-resistant Staphylococcus aureus
2.8.1 Diagnosis
2.8.2 FDA Approved Molecular Tests
2.8.3 Market Opportunity Analysis
2.9 VRE - Vancomycin-resistant Enterococcus
2.9.1 FDA Approved MDx Tests for VRE
2.9.2 Market Opportunity Analysis
2.10 Blood Screening
2.10.1 Collection and Testing
2.10.2 FDA Approved Multiplex Assays
2.10.3 Market Opportunity Analysis

3. Industry Overview
3.1 Industry Participants
3.1.1 IVD Supplier
3.1.2 Independent lab specialized/esoteric
3.1.3 Independent lab national/regional
3.1.4 Independent lab analytical
3.1.5 Public National/regional lab
3.1.6 Hospital lab
3.1.7 Physician lab
3.1.8 Audit body
3.2 The Clinical Laboratory Market Segments
3.2.1 Traditional Market Segmentation
3.2.2 Laboratory Focus and Segmentation
3.3 Industry Structure
3.3.1 Hospital Testing Share
3.3.2 Economies of Scale Hospital vs. Central Lab
3.3.3 Physician Office Lab's
3.3.4 Physician's and POCT
3.4 Profiles of Key MDx Companies

  • Abbott Diagnostics
  • BD Diagnostics
  • Beckman Coulter
  • Biocartis
  • bioMrieux
  • Bio-Rad Laboratories
  • Cepheid
  • Chembio
  • Curetis
  • DiaSorin
  • Eiken Chemical
  • Genedrive
  • Grifols
  • Hologic
  • Illumina
  • Janssen Diagnostics
  • Karius
  • Luminex
  • Meridian Bioscience
  • Qiagen
  • Quidel
  • Roche Molecular Diagnostics
  • Seegene
  • Siemens Healthineers
  • Thermo Fisher

4. Market Trends
4.1 Factors Driving Growth
4.1.1 New Genotypes Creating New Markets
4.1.2 Aging Population a Boon for All Diagnostics
4.1.3 Developing World Driving ID Dx Growth
4.1.4 Point of Care - Why Centralization is Losing Steam
4.1.5 Self Testing
4.1.6 The Need for Speed
4.2 Factors Limiting Growth
4.2.1 Lower Costs
4.2.2 Infectious Disease is Declining.
4.2.3 Wellness Hurts
4.2.4 Economic Growth improves Living Standards
4.3 Instrumentation and Automation
4.3.1 Instruments Key to Market Share
4.3.2 The Shrinking Machine
4.3.2 Multiplex, Point of Care and The Speed Factor
4.4 Diagnostic Technology Development
4.4.1 The Sepsis Testing Market - A New Direction?
4.4.2 POCT/Self Testing as a Disruptive Force
4.4.3 The Genetics Play - One Test for All Known Infections
4.4.4 Antibiotic Resistance Genes - Simplifying Diagnostics

5. Molecular Dx - Infectious Disease Recent Developments
5.1 Recent Developments - Importance and How to Use This Section
5.1.1 Importance of These Developments
5.1.2 How to Use This Section
5.2 Karius Test To Be Available in Brazil
5.3 Panagene's STD kit gains Approval
5.4 Startup Prominex Raises $4M in Series A1
5.5 Quidel Receives FDA Clearance for Its Point-of-Care Sofia Lyme Fluorescent Immunoassa
5.6 'Origami' diagnostics breakthrough set to benefit developing-world farmers
5.7 NYU researchers adapt HIV test to Zika virus
5.8 GA-EMS receives diagnostic device contract
5.9 Biocartis & Immunexpress Sign Partnership for Sepsis
5.10 PerkinElmer to Acquire Euroimmun for $1.3B
5.11 Alveo Closes Financing to Create Accessible Diagnostics Devices
5.12 Siemens Healthineers completes takeover of Fast Track Diagnostics
5.13 Sekisui Diagnostics Enters Strategic Alliance with Mesa Biotech Inc
5.14 Chembio and FIND to Develop Point-of-Care Multiplex Test
5.15 Locus Biosciences and IDbyDNA Partner to Develop Companion Diagnostic Test
5.16 Alere bags FDA nod for rapid flu diagnostic
5.17 FDA approves tests of tick-borne disease to protect blood supply
5.18 Qiagen Trichomonas Assay Gets CE Mark
5.19 Vela Diagnostics HSV Test Gets FDA Clearance
5.20 QIAGEN enters into agreement to acquire STAT-Dx
5.21 Bruker to Acquire Majority Stake in Infectious Disease MDx Firm Hain
5.22 Applied BioCode's Syndromic Gastrointestinal Pathogen Panel Approved by the FDA
5.23 Ares Genetics to develop AI diagnostic test for infectious diseases
5.24 FDA Considers Guidelines for NGS-Based Infectious Disease Diagnostics

6. Country Market Sizes - North America
6.1 United States of America
6.2 Canada

7. Country Markets - Europe
7.1 France
7.2 Germany
7.3 United Kingdom
7.4 Spain
7.5 Italy
7.6 Switzerland
7.7 Czech Republic
7.8 Belgium
7.9 Russia
7.10 Remainder of Europe and Former Soviet Union

8. Country Markets - Asia Pacific
8.1 China
8.2 Japan
8.3 South Korea
8.4 India
8.5 Australia
8.6 Rest of Asia Pacific

9. Country Markets - Latin America, Africa & The Middle East
9.1 Brazil
9.2 Mexico
9.3 Remainder of Latin America
9.4 Africa & The Middle East

10. Global Market Summary
10.1 Global Market

I. United States Medicare System: 2017 Clinical Laboratory Fees Schedule - National Limit and Midpoint
II. FDA Approved Human Genetic Tests
III. FDA Approved Microbial Tests
III. FDA Approved Pharmacogenomics Tests

For more information about this report visit

Media Contact:

Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets

Editor Details

Last Updated: 08-Nov-2018